Outcomes after liver transplantation in accordance with ABO compatibility: A systematic review and meta-analysis
|
|
- Vincent Daniel
- 6 years ago
- Views:
Transcription
1 Submit a Manuscript: DOI: /wjg.v23.i World J Gastroenterol 2017 September 21; 23(35): ISSN (print) ISSN (online) META-ANALYSIS Outcomes after liver transplantation in accordance with ABO compatibility: A systematic review and meta-analysis Eung Chang Lee, Seong Hoon Kim, Sang-Jae Park Eung Chang Lee, Seong Hoon Kim, Sang-Jae Park, Center for Liver Cancer, National Cancer Center, Goyang-si, Gyeonggido , South Korea ORCID number: Eung Chang Lee ( ); Seong Hoon Kim ( ); Sang-Jae Park ( ). Author contributions: Lee EC, Kim SH, Park SJ designed the research; Lee EC performed the research and wrote the paper; Kim SH supervised the study and revised the paper. Conflict-of-interest statement: No conflicts of interest were declared for all authors. Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at kshlj@ ncc.re.kr. No additional data are available. Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: licenses/by-nc/4.0/ Manuscript source: Unsolicited manuscript Correspondence to: Seong Hoon Kim, MD, PhD, Center for Liver Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandonggu, Goyang-si, Gyeonggi-do , South Korea. kshlj@ncc.re.kr Telephone: Fax: Received: May 26, 2017 Peer-review started: May 26, 2017 First decision: June 23, 2017 Revised: July 7, 2017 Accepted: August 15, 2017 Article in press: August 15, 2017 Published online: September 21, 2017 Abstract AIM To evaluate the differences in outcomes between ABOincompatible (ABO-I) liver transplantation (LT) and ABO-compatible (ABO-C) LT. METHODS A systematic review and meta-analysis were performed by searching eligible articles published before November 28, 2016 on MEDLINE (PubMed), EMBASE, and Cochrane databases. The primary endpoints were graft survival, patient survival, and ABO-I-related complications. RESULTS Twenty-one retrospective observational studies with a total of 8247 patients were included in this metaanalysis. Pooled results of patient survival for ABO-I LT were comparable to those for ABO-C LT. However, ABO-I LT showed a poorer graft survival than ABO-C LT (1-year: OR = 0.66, 95%CI: , P < 0.001; 3-year: OR = 0.74, 95% CI , P < 0.001; 5-yearr: OR =0.75, 95%CI: , P < 0.001). Furthermore, ABO-I LT was associated with more incidences of antibody-mediated rejection (OR = 74.21, 95%CI: , P < 0.001), chronic rejection (OR =2.28, 95%CI: , P = 0.05), cytomegalovirus infection (OR = 2.64, 95%CI: , P < 0.001), overall biliary complication (OR = 1.52, 95%CI: , P = 0.04), and hepatic artery complication (OR = 4.17, 95%CI: , P < 0.001) than ABO-C LT. In subgroup analyses, ABO-I LT and ABO-C LT showed a comparable graft survival in pediatric patients and those using rituximab, and ABO-I LT showed an 6516 September 21, 2017 Volume 23 Issue 35
2 increased acute cellular rejection in cases involving deceased donor grafts. CONCLUSION Although patient survival in ABO-I LT was comparable to that in ABO-C LT, ABO-I LT was inferior to ABO-C LT in graft survival and several complications. Graft survival of ABO-I LT could be comparable to that of ABO-C LT in pediatric patients and those using rituximab. Key words: ABO-incompatibility; Liver transplantation; Graft survival; Patient survival; Complications The Author(s) Published by Baishideng Publishing Group Inc. All rights reserved. Core tip: This meta-analysis analyzed more than 8000 cases of ABO-incompatible (ABO-I) and ABOcompatible (ABO-C) liver transplantation (LT). Although patient survival was similar, ABO-I LT was inferior to ABO-C LT in graft survival and several ABO-Irelated complications. Graft survival of ABO-I LT was comparable to that of ABO-C LT in pediatric patients and those using rituximab. Lee EC, Kim SH, Park SJ. Outcomes after liver transplantation in accordance with ABO compatibility: A systematic review and meta-analysis. World J Gastroenterol 2017; 23(35): Available from: URL: v23/i35/6516.htm DOI: i INTRODUCTION In an animal experiment in 1969, Starzl et al [1] reported that the liver is a privileged organ that could be transplanted with relatively lower prevalence of acute rejection than those associated with the kidney or heart. Furthermore, in 1979, Starzl et al [2] reported 11 cases of successful ABO-incompatible (ABO-I) liver transplantation (LT) without graft rejections [2]. Since then, however, there has been a series of reports of heightened prevalence of antibody-mediated rejection (AMR), lower graft survival, hepatic artery thrombosis (HAT), and cholangitis in ABO-I LT compared to ABOcompatible (ABO-C) LT [3-6]. Nevertheless, the application of various desensitization strategies, such as plasma exchange (PE) (or plasmapheresis), splenectomy, graft local infusion (GLI), mycophenolate mofetil (MMF), rituximab, and intravenous immunoglobulin (IVIG) to ABO-I LT highlight the potential of ABO-I LT as a promising alternative to ABO-C LT, and the introduction of rituximab has brought about substantial improvements in the outcomes of ABO-I LT [7-12]. Currently, its importance is expanding in the East, where the proportion of uses of ABO-I allografts for living donor liver transplantation (LDLT) is higher than that in the West, and particularly in Korea and Japantwo countries that show notably higher proportions of interfamilial organ donation. However, there are still heated debates with regard to the prevalence of graft survival, patient survival, ABO-I-related complications, such as rejection, infection, biliary stricture, and HAT associated with ABO-I LT and ABO-C LT, with much heterogeneity in different reports. Therefore, considering the fact that cases of ABO-I LT would inevitably rise due to demands for donor organs far outnumbering the supply and increased difficulty of matching appropriate ABO-C liver allografts, a comprehensive analysis of the results from previous reports of LT across the ABO blood group barrier is needed. MATERIALS AND METHODS Study selection Systematic review and meta-analysis were performed in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines [13]. Databases of Medline (Pubmed), EMBASE, and Cochrane library were used to search for relevant articles among publications dated November 28, Publication year and language were not specified or limited for the search. The following keywords for the database search were used: (ABO OR = blood group OR = blood type) AND (incompatibility OR = mismatch OR = barrier) AND liver transplantation. Title and abstracts of identified articles were screened independently by two investigators (Lee EC, Shim JR ), and full-text articles with potential relevance were obtained. Eligibility criteria The included studies were articles that compared ABO-I LT and ABO-C LT with a minimum of one outcome of interest. The following types of articles were excluded: abstracts, meeting papers, case reports/series, reviews, meta-analyses, letters, editorial comments, animal studies, single-arm studies, and studies unable to extract data. When there were overlapping cohorts examined by the same institutions, data from the most recent studies were used. Assessment of methodological quality Because there was no randomized controlled trial study included in this review, methodological quality was assessed based on a maximum score of 9 for selection of patients, comparability, and outcome of study as per the Newcastle-Ottawa Quality Assessment Scale for Cohort Studies [14]. All of the studies included in this meta-analysis were assessed by two investigators (Lee EC, Shim JR), and disagreements were resolved by a consensus September 21, 2017 Volume 23 Issue 35
3 Data extraction Data for the following items were extracted: first author, publication year, study periods, region, sample size, population, recipient age, donor age, urgent indication, donor type, prescription for ABO-I LT, immunosuppression, graft survival, patient survival, AMR, acute cellular rejection (ACR), CR (chronic rejection), bacterial infection, fungal infection, cytomegalovirus (CMV) infection, overall biliary complication, bile leak, biliary stricture, hepatic artery (HA) complication, hepatic vein (HV) complication, and portal vein (PV) complication. For studies that divided ABO-C LT into ABO-C non-identical LT and ABO- Identical (ABO-Id) LT and reported separate outcomes for each [15-20], the outcomes were combined for the purpose of this meta-analysis. If the required data were not clearly articulated in the selected articles, we requested the original data via an to the corresponding authors. All data were independently investigated and cross-checked by two investigators (Lee EC, Shim JR), and another investigator (Kim SH) provided the final confirmation. Statistical analysis This meta-analysis was performed in compliance with the Cochrane guidelines for systematic revie [21]. Categorical variables were analyzed with odds ratios (OR) with 95% confidence interval (CI) using the Mantel-Haenszel method, and continuous variables were analyzed with weighted mean differences (WMD) with 95%CI using an inverse variance method. Heterogeneity among studies was assessed with Higgin s I 2 index [22] or Cochran s Q test [21,23]. The random-effects model was used when I 2 was > 50% or P-value (Cochran s Q test) was < 0.10, and the fixed-effects model was used in all other cases. Heterogeneous results were further examined with a sensitivity analysis using the leave-one-out method and subgroup analyses. Possible publication bias was assessed using funnel plots and Egger s regression test, which evaluates a funnel plot asymmetry [24,25]. If a publication bias with P-value < 0.10 (Egger s regression test) was detected, the impact on the outcomes of the meta-analysis was assessed after enhancing the symmetry using the trim-andfill method of Duvall and Tweedie [26]. The presence of publication bias in fewer than 10 studies was considered unreliable as per the Cochrane Handbook for Systematic Reviews [27]. A P-value of < 0.05 was considered statistically significant. Statistical analyses were performed using the Review Manager (RevMan) software version 5.3 ( revman) and R package meta ( org/web/packages/meta). RESULTS Search results A total of 986 citations were found in the primary search using combinations of keywords for database search, of which 762 irrelevant or duplicated citations were excluded. After retrieving the titles and abstracts from the remaining 224 articles, another 186 articles were excluded. From the 38 potentially relevant studies, additional studies were excluded for the following reasons: single-arm studies (n = 9), overlapping cohorts from the same institutions (n = 4), studies investigating multiple desensitization protocols (n = 1), timing of rituximab administration (n = 1), and pathology (n = 1), and unable data extraction (n = 1). As a result, 21 studies were included in this meta-analysis [5,15-20,28-41]. The flow diagram of study selection is shown in Figure 1. Characteristics of included studies This meta-analysis included 21 retrospective observational studies that were conducted on a total of 8247 patients [5,15-20,28-41]. Of these patients, 1494 underwent ABO-I LT, while 6753 underwent ABO-C LT. There has been no randomized clinical trial conducted on this topic. Study periods ranged from For studies involving less than 10% heterogeneity in study population (adult vs pediatric), donor type (deceased vs living), urgent indication [i.e., fulminant hepatic failure (FHF), acute liver failure (ALF), retransplantation, and critically ill patients in the intensive care unit], and use of rituximab for ABO-I LT, these parameters were classified according to the majority. One registry study was included in this metaanalysis [35]. Characteristics of the included studies are summarized in Table 1. Methodological quality assessment All studies included in this meta-analysis showed a Newcastle-Ottawa Scale (NOS) score 6. Four case or propensity score matched studies were included [29,30,35,41]. Quality assessments of included cohort studies are presented in Table 2. Graft and patient survival Graft survival and patient survival were reported by 16 and 15 studies, respectively. ABO-I LT showed poorer outcomes than those of ABO-C LT in the pooled results of graft survival (1-year: OR = 0.66, 95%CI: , P < 0.001; 3-year: OR = 0.74, 95%CI: , P < 0.001; 5-year: OR = 0.75, 95%CI: , P < 0.001; 10-year: OR = 0.80, 95%CI: , P = 0.004; Figure 2). There were no differences in 1-, 3-, and 5-year patient survival in accordance with ABO compatibility (1-year: OR = 0.88, 95%CI: , P = 0.38; 3-year: OR = 0.89, 95%CI: , P = 0.47; 5-year: OR = 0.89, 95%CI: , P = 0.45; Figure 3). However, there was a significant difference in the 10-year patient survival between ABO-I and ABO-C groups (10-year: OR = 0.46, 95%CI: , P = 0.004; Figure 3). There was no significant 6518 September 21, 2017 Volume 23 Issue 35
4 Citations identified in primary search (n = 986) Irrelevant studies (n = 415) Duplicated studies (n = 347) Titles and abstracts screening (n = 224) Abstract/meeting (n = 104) Case reports/series (n = 50) Reviews/meta-analysis (n = 15) Letters/editorial comments (n = 9) Animal studies (n = 1) Others (n = 7) Potentially relevant studies (n = 38) Single-arm studies (n = 9) Overlapping cohorts (same institution) (n = 4) Studies investigating multiple desensitization protocols (n = 1), timing of rituximab administration (n = 1), and pathology (n = 1) Unable data extracting (n = 1) Eligible studies included in the meta-analysis (n = 21) Figure 1 Flow diagram showing the selection of articles for meta-analysis. heterogeneity in graft and patient survival. Complications Rejection: AMR, ACR, and CR were reported by 4, 14, and 4 studies, respectively. Pooled results showed that the risks for AMR (OR = 74.21, 95%CI , P < 0.001; Figure 4A) and CR (OR = 2.28, 95%CI: , P = 0.05; Figure 4C) were significantly higher in ABO-I LT than in ABO-C LT, but there was no statistically significant difference in the risk for ACR (OR = 1.23, 95%CI: , P = 0.15; Figure 4B). There was no significant heterogeneity in the results for rejection. Infection: Bacterial and fungal infections were each reported by 4 studies, while CMV infection was reported by 5 studies. Although there were no differences in bacterial infection (OR = 0.72, 95%CI: , P = 0.16; Figure 4D) and fungal infection (OR = 0.66, 95%CI: , P = 0.16; Figure 4E) in accordance with ABO-compatibility, CMV infection was more prevalent in ABO-I LT than in ABO-C LT (OR = 2.64, 95%CI: , P < 0.001; Figure 4F). There was no significant heterogeneity in the results for infection. Biliary: There were no statistically significant differences in overall biliary complication (OR = 1.75, 95%CI: , P = 0.10; Figure 5A), bile leak (OR = 1.85, 95%CI: , P = 0.39; Figure 5B), and biliary stricture (OR = 1.37, 95%CI: , P = 0.36; Figure 5C) in accordance with ABO compatibility. However, there were high heterogeneities in overall biliary complication (χ 2 = 15.22, degree of freedom [d.f.] = 7, P = 0.03; I 2 = 54%), bile leak (χ 2 = 4.25, d.f. = 2, P = 0.12; I 2 = 53%), and biliary stricture (χ 2 = 9.36, d.f. = 5, P = 0.10; I 2 = 47%). Vascular: HA complication (OR = 4.17, 95%CI: , P < 0.001; Figure 5D) was significantly more prevalent in ABO-I LT than in ABO-C LT. However, there were no significant differences between ABO-I LT and ABO-C LT in HV complication (OR = 1.60, 95%CI: , P = 0.32; Figure 5E) and PV complication (OR = 1.83, 95%CI: , P = 0.22; Figure 5F). There was no severe heterogeneity in vascular complications. Sensitivity and subgroup analyses In this meta-analysis, there were high heterogeneities in overall biliary complication, bile leak, and biliary stricture. We performed a sensitivity analysis on these variables using the leave-one-out method and found that omitting the study of Sanchez et al [41] with a wide range of CI (overall biliary complication: OR = 85.00, 95%CI: ; Bile leak: OR = 10.82, 95%CI: ) eliminated the heterogeneity in overall biliary complication and bile leak. Particularly, postsensitive analysis results showed that ABO-I LT was associated with higher prevalence of overall biliary complications than ABO-C LT (OR = 1.52, 95%CI: , P = 0.04; Table 3) September 21, 2017 Volume 23 Issue 35
5 Table 1 Characteristics of the included studies Ref. Publication (yr) Study periods (yr) Region Arms Sample size Population 3 Recipient age Donor age Urgent Donor type 3 Prescription for ABO-I LT Immunosuppression Indications 3,4 Song et al[ 28] South Korea ABO-I 235 Adult 52.8 ± ± 9.1 No Living Rituximab, PE, GLI (±), Splenectomy Steroids, Basiliximab,Tac, MMF ABO-C ± ± 7.6 (±), Cyclophosphamide Kim et al [29] South Korea ABO-I 472 Adult 50 (22-65) 32 (18-68) No Living Rituximab, PE, GLI (±) Steroids, Basiliximab, Tac, MMF ABO-C (20-68) 30 (18-62) Kim et al [30] South Korea ABO-I 252 Adult 51.3 ± ± 11.2 No Living Rituximab, PE, IVIG, Preoperative Steroids, Basiliximab, Tac, MMF ABO-C ± ± 11.3 MMF Ikegami et al [31] Japan ABO-I 19 Adult 47.7 ± ± 11.3 No Living Rituximab3, IVIG (±), PE, GLI (±), Steroids, Tac (or CsA), MMF ABO-C ± ± 10.5 Splenectomy (±), Preoperative MMF (±) Lee et al [32] Taiwan ABO-I 46 Adult 53.5 (19-67) NA No Living Rituximab, Plasmapheresis (or PE) Steroids, Tac, MMF ABO-C (18-70) NA Shen et al [33] China ABO-I 35 Adult 46.7 ± 12.1 NA Yes Deceased Rituximab, IVIG Steroids, Basiliximab, Tac, MMF ABO-C ± 10.2 NA Heffron et al [34] ABO-C 21 NA NA United States ABO-I 12 Pediatric NA NA Yes Deceased - Steroids, Daclizumab, Tac, MMF Stewart et al [35] United States ABO-I 1302 Infant No Deceased NA NA ABO-C ABO-I 1162 Pediatric ABO-C ABO-I 5852 Adult ABO-C Iwamoto Japan ABO-I 15 Adult NA NA No Living NA NA et al [36] ABO-C 37 NA NA Toso et al [20] Canada ABO-I 14 Adult 42 (17-61) NA Yes Deceased Lymphocyte-depleting antibodies5, Plasmapheresis (±) ABO-C (16-62) NA ABO-Id (17-66) NA Steroids, Daclizumab, CsA (or Tac), AZA (or MMF, Sirolimus) Saito et al [37] Japan ABO-I 10 All ages NA NA No Deceased, NA NA ABO-C 81 NA NA Living Koukoutsis United et al [19] Kingdom ABO-I 4 Adult NA NA Yes Deceased NA NA ABO-C1 73 NA NA ABO-Id 203 NA NA Ueda et al [18] United States ABO-I 16 Pediatric 6.5 ± 6.2 NA No Deceased Plasmapheresis (±) Steroids, Daclizumab, Tac, MMF Japan ABO-I 74 Pediatric NA NA No Living Steroids pulse weekly, PGE1, CsA - > Steroids, Tac ABO-C1 114 NA NA AZA (1 mo after LT) ABO-Id 380 NA NA Heffron et al [38] ABO-C ± 6.2 NA Bjøro et al [17] Nordic countries ABO-I 10 All ages NA 44.8 (22-55) Yes Deceased NA NA ABO-C 76 NA 42.3 (12-85) ABO-Id 143 NA 41.0 (2-75) Chui et al [39] Australia ABO-I 7 All ages 13 (6-32) NA Yes Deceased Plasmapheresis (±), Splenectomy (±) Steroids, CsA, AZA ABO-C 36 NA NA Cacciarelli ABO-C ± 1.0 NA ABO-Id ± 0.5 NA et al [16] Tac United States ABO-I 14 Pediatric 2.2 ± 1.1 NA No Deceased OKT3 (or ATG, CsA) Steroids, ATG (or OKT3, CsA), 6520 September 21, 2017 Volume 23 Issue 35
6 Lo et al [40] United States ABO-I 29 All ages NA NA Yes Deceased ATG (±) Steroids, CsA (or OKT3), AZA ABO-C 196 NA NA Sanchez et al [41] ABO-C (17-59) NA United States ABO-I 182 Adult 45 (16-61) NA No Deceased NA NA 30 Reding Belgium ABO-I 16 All ages NA NA Yes Deceased OKT3 (±) Steroids, CsA, AZA(±) et al [15] ABO-C 16 NA NA ABO-Id 38 NA NA Gugenheim France ABO-I 17 All ages (12-49) NA Yes Deceased - Steroids, CsA, AZA et al [5] ABO-C 217 NA NA 1 Compatible, but not identical; 2 Propensity or case matched patients; 3 If there are minority groups that make up less than about 10%, the article is categorized as covering the majority; 4 Such as FHF, ALF, retransplantation, and critically ill patients in the intensive care unit; 5 Documented as "lymphocyte-depleting antibodies", but not clarified exactly. ABO-C: ABO-compatible; ABO-I: ABO-incompatible; ABO-Id: ABO-identical; ATG: anti-thymocyte globulin; AZA: Azathioprine; CsA: Cyclosporin A; GLI: Graft local infusion; IVIG: Intravenous immunoglobulin; LT: Liver transplantation; MMF: Mycophenolate mofetil; NA: Not applicable; OKT3: Muromonab-CD3; PE: Plasma exchange; Tac: Tacrolimus. Although there were no significant heterogeneities in most comparisons, such as in graft survival, patient survival, and complications, we attempted to minimize potential heterogeneities and detail the subgroup-specific differences through subgroup analyses. Possible confounding factors-the parameters that were speculated to impact the outcomes of this meta-analysis-included study population (adult vs pediatric), use of rituximab for ABO-I LT, urgent indication, and donor type (deceased vs living). There were no significant differences in most subgroup comparisons. However, studies that involved pedia-tric patients [16,18,34,35,38] showed better 1-year (OR = 0.88, 95%CI: vs OR = 0.59, 95%CI: ; P = 0.01) and 3-year graft survivals (OR = 0.95, 95%CI: vs OR = 0.67, 95%CI: ; P = 0.04) after ABO-I LT than those involving adult patients. Furthermore, in such studies, there were no significant differences between ABO-I LT and ABO-C LT in 1-, 3-, 5-, and 10-year graft survivals (1-year: OR=0.88, 95%CI: , P = 0.35; 3-year: OR = 0.95, 95%CI: , P = 0.71; 5-year: OR = 0.82, 95%CI: , P = 0.14; 10-year: OR = 0.71, 95%CI: , P = 0.22). Meanwhile, using rituximab in ABO-I LT patients [28-33] showed better 1-year graft survival (OR = 0.88, 95%CI: vs OR = 0.44, 95%CI: ; P = 0.02) after ABO-I LT compared to cases not using rituximab [15,16,18, 34,38-40, 42]. Moreover, in such cases, 1-, 3-, and 5-year graft survival of ABO-I LT were not significantly different from those of ABO-C LT (1-year: OR = 0.88, 95%CI: , P = 0.55; 3-year: OR = 0.81, 95%CI: , P = 0.28; 5-year: OR = 0.96, 95%CI: , P = 0.83). On the other hand, when rituximab was not used, incidence of biliary stricture (OR = 1.00, 95%CI: vs OR=4.32, 95%CI: ; P = 0.06) and ACR (OR = 0.86, 95%CI: vs OR = 1.61, 95%CI: ; P = 0.048) tended to be higher in ABO-I LT than in ABO-C LT. However, there was no difference in AMR incidence (OR=48.32, 95%CI: vs OR = , 95%CI: ; P = 0.45) and patient survival (1-year: OR = 0.88, 95% CI vs OR = 0.67, 95%CI: , P = 0.38; 3-year: OR = 0.90, 95%CI: vs OR = 0.80, 95%CI: , P = 0.82; 5-year: OR = 0.90, 95%CI: vs OR = 1.00, 95%CI: , P = 0.89) in accordance with the use of rituximab. Studies that involved urgent indica-tions [15,17,19,20,33,34,39,40,42] had worse 1-year graft survival (OR = 0.37, 95%CI: vs OR=0.70, 95%CI: ; P = 0.01) but better 5-year patient survival (OR = 2.38, 95%CI: vs OR = 0.79, 95%CI: , P = 0.043) for ABO-I LT than those for ABO-CT when compared to studies without urgent indications. In addition, compared to cases that involved the use of deceased donor liver allografts, those that involved the use of living donor liver allografts [18,28-32,36] showed lower prevalence of ACR (OR = 0.87, 95%CI: vs OR = 1.69, 95%CI: ; P = 0.02) and biliary stricture (OR = 1.00, 95%CI: vs OR = 4.49, 95%CI: ; P = 0.04) in ABO-I LT. Results of sensitivity analysis and subgroup analysis are summarized in Table 3. Publication bias In this meta-analysis, 1-year patient survival was found to have a potential publication bias with a funnel plot asymmetry (Figure 6A) and a P = 0.06 calculated by the Egger s regression test. Other variables did not show a significant publication bias. After adjusting for funnel plot asymmetry using the trim-and-fill method [26] (Figure 6B), ABO-I LT showed a significantly poorer 1-year patient survival than ABO-C LT (OR=0.73, 95%CI: , P = 0.02; I 2 = 25.8%) September 21, 2017 Volume 23 Issue 35
7 Study or Subgroup Events Total Events Total Weight M-H.Fixed. 95%CI M-H. Fixed. 95%CI A 1-yr graft survival Song % 0.75 [0.43, 1.33] Ikegami % 2.35 [0.31, 18.06] Lee % 1.12 [0.50, 2.52] Shen % 0.63 [0.21,1.87] Heffron % 0.55 [0.03, 9.68] Stewart % 0.69 [0.58, 0.81] Toso % 0.93 [0.29, 3.00] Koukoutsis % 0.59 [0.08, 4.23] Ueda % 0.58 [0.32, 1.06] Heffron % 2.94 [0.37, 23.55] Bjøro % 0.28 [0.08, 1.03] Chui % 0.42 [0.08, 2.19] Cacciarelli % 0.48 [0.14, 1.68] Sanchez % 0.23 [0.05, 0.97] Reding % 0.29 [0.07, 1.13] Gugenheim % 0.10 [0.03, 0.29] Subtotal(95% CI) % 0.66 [0.57, 0.76] Total events Heterogeneity: χ 2 = 23.51, df = 15 (P = 0.07); I 2 = 36% Test for overall effect: Z = 5.82 (P < ) B 3-yr graft survival Song % 0.76 [0.48, 1.22] Lee % 1.04 [0.51, 2.15] Shen % 0.63 [0.21, 1.87] Heffron % 0.71 [0.13, 3.87] Stewart % 0.73 [0.62, 0.85] Chui % 0.42 [0.08, 2.19] Cacciarelli % 0.69 [0.20, 2.35] Subtotal (95% CI) % 0.74 [0.64, 0.85] Total events Heterogeneity: χ 2 = 1.48, df = 6 (P = 0.96); I 2 = 0% Test for overall effect: Z = 4.17 (P < ) C 5-yr graft survival Song % 0.84 [0.53, 1.34] Ikegami % 2.10 [0.47, 9.27] Lee % 1.01 [0.51, 2.01] Stewart % 0.74 [063, 0.87] Toso % 0.95 [0.30, 2.94] Koukoutsis % 0.22 [0.02, 2.18] Ueda % 0.59 [0.33, 1.03] Chui % 0.42 [0.08, 2.19] Subtotal(95% CI) % 0.75 [0.66, 0.86] Total events Heterogeneity: χ 2 = 5.32, df = 7 (P = 0.62); I 2 = 0% Test for overall effect: Z = 4.02 (P < ) D 10-yr graft survival Stewart % 0.84 [0.71, 0.98] Ueda % 0.51 [0.31, 0.85] Subtotal(95%CI) % 0.80 [0.69, 0.93] Total events Heterogeneity: χ 2 = 3.25, df = 1 (P = 0.07); I 2 = 69% Test for overall effect: Z = 2.85 (P = 0.004) Total (95%CI) % 0.73 [0.68, 0.79] Total events Heterogeneity: χ 2 = 37.26, df = 32 (P = 0.24); I 2 = 14% Test for overall effect: Z = 8.44 (P < ); Test for subgroup differences: Not applicable Favours ABO-C Favours ABO-I Figure 2 Comparison of graft survival between ABO-incompatible and ABO-compatible liver transplantation. ABO-C: ABO-compatible; ABO-I: ABOincompatible; LT: Liver transplantation September 21, 2017 Volume 23 Issue 35
8 Table 2 Modified Newcastle-Ottawa quality assessment scale for cohort studies included in the meta-analysis Ref. Selection Comparability 1 Outcome Overall Representativeness Selection Ascertainment Incident disease Assessment Length of follow-up Adequacy of follow-up Quality Score (Maximum 9) Song et al [28] 6 Kim et al [29] 8 Kim et al [30] 8 Ikegami 6 et al [31] Lee et al [32] 6 Shen et al [33] 6 Heffron 6 et al [34] Stewart 8 et al [35] Iwamoto 6 et al [36] Toso et al [20] 6 Saito et al [37] 6 Koukoutsis 6 et al [19] Ueda et al [18] 6 Heffron 6 et al [38] Bjøro et al [17] 6 Chui et al [39] 6 Cacciarelli 6 et al [16] Lo et al [40] 6 Sanchez 8 et al [41] Reding 6 et al [15] Gugenheim et al [5] 6 1 A maximum of two downward arrows ( ) can be given for comparability. : Consistent with criteria and low risk of bias; : Not consistent with criteria and high risk of bias. DISCUSSION Since the first attempt of ABO-I LT by Starzl et al [1,2], poor outcomes after ABO-I LT, including AMR, lower graft survival, HAT, and cholangitis, were insurmountable barriers for expanding the application of transplantation across the ABO blood group barrier, from a few urgent cases to cases of chronic liver disease and liver cancer [3-6]. Extraordinary improvements have been made in the outcomes of ABO-I LT with the introduction of multiple desensitization strategies, such as PE (or plasmapheresis), splenectomy, GLI, rituximab, MMF, and IVIG, as well as with advances of immunosuppression agents [7-12]. However, whether ABO-I LT is comparable to ABO-C LT remains a topic of debate. This meta-analysis revealed that pooled results of graft survival were poorer in ABO-I LT than in ABO-C LT. However, patient survival did not significantly vary in accordance with ABO compatibility in most cases. The data on 10-year patient survival had low reliability, as they were only reported by one study-although produced based on a long-term follow-up [18]. Meanwhile, the cumulative meta-analysis in order by the median year of study period showed that the cumulative results of graft and patient survival remained consistent since the early 2000s (Supplementary Figures 1 and 2). This is mainly due to the stabilization of the desensitization protocol through the application of PE (or plasmapheresis) [42-44], muromonab-cd3 (OKT3) [42-44], splenectomy [9], PV infusion [10,45], HA infusion [46,47], rituximab [48-50], and IVIG [7,8,51] in ABO-I LT. However, from a different perspective, the fact that ABO-I LT patients showed a poorer graft survival than ABO-C LT patients and that cumulative meta-analysis of graft survival remained mostly unchanged since the early 2000s implies that the current desensitization protocol for ABO-I LT still requires an improvement. With regard to ABO-I-related complications, the prevalence of AMR, CR, CMV infection, and HA complication was higher in ABO-I LT than in ABO-C LT. Overall biliary complication-after omitting a study of Sanchez et al [41] with a wide range of CI in the 6523 September 21, 2017 Volume 23 Issue 35
9 A 1-yr patient survival Song % 0.72 [0.41, 1.27] Kim % 1.23 [0.41, 3.72] Lee % 1.12 [0.50, 2.52] Shen % 0.76 [0.25, 2.35] Heffron % 0.55 [0.03, 9.68] Toso % 2.81 [0.59, 13.36] Koukoutsis % 1.50 [0.15, 14.62] Ueda % 0.61 [0.33, 1.12] Heffron % 2.76 [0.15, 49.72] Bjøro % 0.80 [0.20, 3.21] Chui % 3.39 [0.37, 31.34] Cacciarelli % 0.48 [0.12, 1.91] Sanchez % 4.00 [0.85, 18.84] Reding % 0.67 [0.22, 2.06] Gugenheim % 0.43 [0.14, 1.30] Subtotal (95% CI) % 0.88 [0.67, 1.16] Total events Heterogeneity: χ 2 = 13.41, df = 14 (P = 0.49); I 2 = 0% Test for overall effect: Z = 0.88 (P = 0.38) B 3-yr patient survival Song % 0.74 [0.46, 1.18] Kim % 1.54 [0.60, 3.96] Lee % 1.04 [0.51, 2.15] Shen % 0.76 [0.25, 2.35] Heffron % 0.15 [0.01, 1.65] Chui % 3.39 [0.37, 31.34] Cacciarelli % 0.71 [0.18, 2.75] Subtotal (95% CI) % 0.89 [0.64, 1.23] Total events Heterogeneity: χ 2 = 5.79, df = 6 (P = 0.45); I 2 = 0% Test for overall effect: Z = 0.73 (P = 0.47) C 5-yr patient survival Song % 0.84 [0.53, 1.34] Lee % 1.01 [0.51, 2.01] Toso % 2.28 [0.59, 8.71] Koukoutsis % 1.79 [0.18, 17.40] Ueda % 0.58 [0.32, 1.02] Chui % 3.39 [0.37, 31.34] Subtotal (95% CI) % 0.89 [0.66, 1.20] Total events Heterogeneity: χ 2 = 6.03, df = 5 (P = 0.30); I 2 = 17% Test for overall effect: Z = 0.73 (P = 0.45) D10-yr patient survival Ueda % 0.46 [0.28, 0.78] Subtotal (95% CI) % 0.46 [0.28, 0.78] Total events Heterogeneity: Not applicable Test for overall effect: Z = 2.89 (P = 0.004) Total (95% CI) % 0.84 [0.71, 0.98] Total events Heterogeneity: χ 2 = 29.99, df = 28 (P = 0.36); I 2 = 7% Test for overall effect: Z = 2.17 (P = 0.03) Test for subgroup differences: Not applicable Favours ABO-C Favours ABO-I Figure 3 Comparison of patient survival between ABO-incompatible and ABO-compatible liver transplantation. ABO-C: ABO-compatible; ABO-i: ABOincompatible; LT: Liver transplantation. sensitivity analysis-was more prevalent in ABO-I LT than in ABO-C LT. In the subgroup analyses, studies that only involved pediatric patients [16,18,34,35,38], compared to those that did not, showed better 1-year and 3-year graft survivals after ABO-I LT than those after ABO-C LT. Furthermore, in such cases, 1-, 3-, 5-, and 10-year graft survivals after ABO-I LT were comparable to those after ABO-C LT. There were several reports that pediatric ABO-I LT was more successful than 6524 September 21, 2017 Volume 23 Issue 35
10 Table 3 Sensitivity analysis and subgroup analysis Variables No. of studies OR=[95%CI] P 1 value I 2 (%) Sensitivity analysis Overall biliary complication 1.75 [ ] Omitting Sanchez et al [41] [ ] Omitting Cacciarelli et al [16] [ ] Omitting Heffron et al [38] [ ] Omitting Toso et al [20] [ ] Omitting Iwamoto et al [36] [ ] Omitting Shen et al [33] [ ] Omitting Lee et al [32] [ ] Omitting Kim et al [29] [ ] Bile leak 1.85 [ ] Omitting Sanchez et al [41] [ ] Omitting Kim et al [30] [ ] Omitting Kim et al [29] [ ] Biliary stricture 1.37 [ ] Omitting Sanchez et al [41] [ ] Omitting Lo et al [40] [ ] Omitting Ikegami et al [31] [ ] Omitting Kim et al [30] [ ] Omitting Kim et al [29] [ ] Omitting Song et al [28] [ ] Subgroup analysis 1-yr graft survival 0.66 [ ] < Rituximab for ABO-I LT (yes/no) 4 vs [ ] vs 0.44 [ ] vs 49 Living donor (yes/no) 4 vs [ ] vs 0.64 [ ] vs 44 Urgent indication (yes/no) 8 vs [ ] vs 0.70 [ ] vs 8 Pediatric2 (yes/no) 5 vs [ ] vs 0.59 [ ] vs 45 3-yr graft survival 0.74 [ ] < Rituximab for ABO-I LT (yes/no) 3 vs [ ] vs 0.60 [ ] vs 0 Living donor (yes/no) 2 vs [ ] vs 0.72 [ ] vs 0 Urgent indication (yes/no) 3 vs [ ] vs 0.74 [ ] vs 0 Pediatric2 (yes/no) 3 vs [ ] vs 0.67 [ ] vs 0 5-yr graft survival 0.75 [ ] < Rituximab for ABO-I LT (yes/no) 3 vs [ ] vs 0.56 [ ] vs 0 Living donor (yes/no) 4 vs [ ] vs 0.73 [ ] vs 0 Urgent indication (yes/no) 3 vs [ ] vs 0.76 [ ] vs 0 Pediatric 2 (yes/no) 2 vs [ ] vs 0.73 [ ] vs 0 10-yr graft survival 0.80 [ ] Rituximab for ABO-I LT (yes/no) 0 vs 1 NA vs 0.51 [ ] NA NA Living donor (yes/no) 1 vs [ ] vs 0.84 [ ] 0.07 NA vs NA Urgent indication (yes/no) 0 vs 2 NA vs 0.70 [ ] NA NA vs 69 Pediatric 2 (yes/no) 2 vs [ ] vs 0.81 [ ] vs NA 1-yr patient survival 0.88 [ ] Rituximab for ABO-I LT (yes/no) 4 vs [ ] vs 0.67 [ ] vs 0 Living donor (yes/no) 4 vs [ ] vs 1.04 [ ] vs 9 Urgent indication (yes/no) 8 vs [ ] vs 0.87 [ ] vs 21 Pediatric (yes/no) 4 vs [ ] vs 0.98 [ ] vs 5 3-yr patient survival 0.89 [ ] Rituximab for ABO-I LT (yes/no) 4 vs [ ] vs 0.80 [ ] vs 43 Living donor (yes/no) 3 vs [ ] vs 0.78 [ ] vs 15 Urgent indication (yes/no) 3 vs [ ] vs 0.90 [ ] vs 0 Pediatric (yes/no) 2 vs [ ] vs 0.94 [ ] vs 0 5-yr patient survival 0.89 [ ] Rituximab for ABO-I LT (yes/no) 2 vs [ ] vs 1.00 [ ] vs 57 Living donor (yes/no) 3 vs [ ] vs 2.38 [ ] vs 0 Urgent indication (yes/no) 3 vs [ ] vs 0.79 [ ] vs 0 Pediatric (yes/no) 1 vs [ ] vs 1.04 [ ] 0.09 NA vs 0 10-yr patient survival 0.46 [ ] Rituximab for ABO-I LT (yes/no) 0 vs 1 NA vs 0.46 [ ] NA NA Living donor (yes/no) 1 vs [ ] vs NA NA NA Urgent indication (yes/no) 0 vs 1 NA vs 0.46 [ ] NA NA Pediatric (yes/no) 1 vs [ ] vs NA NA NA ACR 1.23 [ ] Rituximab for ABO-I LT (yes/no) 5 vs [ ] vs 1.61 [ ] vs 0 Living donor (yes/no) 4 vs [ ] vs 1.69 [ ] vs 0 Urgent indication (yes/no) 6 vs [ ] vs 1.08 [ ] vs September 21, 2017 Volume 23 Issue 35
11 Pediatric (yes/no) 3 vs [ ] vs 1.16 [ ] vs 0 CR 2.28 [ ] Rituximab for ABO-I LT (yes/no) 2 vs [ ] vs 2.64 [ ] vs 0 Living donor (yes/no) 2 vs [ ] vs 2.64 [ ] vs 0 Urgent indication (yes/no) 2 vs [ ] vs 6.45 [ ] vs 80 Pediatric (yes/no) 0 vs 4 NA vs 2.28 [ ] NA NA vs 42 AMR [ ] < Rituximab for ABO-I LT (yes/no) 2 vs [ ] vs [ ] vs NA Living donor (yes/no) 1 vs [ ] vs [ ] 0.3 NA vs 18 Urgent indication (yes/no) 3 vs [ ] vs [ ] vs NA Pediatric (yes/no) 0 vs 4 NA vs [ ] NA NA vs 12 Bacterial infection 0.72 [ ] Rituximab for ABO-I LT (yes/no) 4 vs [ ] vs NA NA 0 vs NA Living donor (yes/no) 3 vs [ ] vs 0.84 [ ] vs NA Urgent indication (yes/no) 1 vs [ ] vs 0.70 [ ] 0.75 NA vs 0 Pediatric (yes/no) 0 vs 4 NA vs 0.72 [ ] NA NA vs 0 Fungal infection 0.66 [ ] Rituximab for ABO-I LT (yes/no) 3 vs [ ] vs NA NA 0 vs NA Living donor (yes/no) 2 vs [ ] vs 0.63 [ ] vs 62 Urgent indication (yes/no) 2 vs [ ] vs 0.65 [ ] vs 0 Pediatric (yes/no) 0 vs 4 NA vs 0.71 [ ] NA NA vs 0 CMV infection 2.64 [ ] < Rituximab for ABO-I LT (yes/no) 3 vs [ ] vs NA NA 4 vs NA Living donor (yes/no) 3 vs [ ] vs 6.43 [ ] vs 82 Urgent indication (yes/no) 1 vs [ ] vs 2.77 [ ] 0.4 NA vs 53 Pediatric (yes/no) 0 vs 5 NA vs 2.64 [ ] NA NA vs 43 Overall Biliary complication 1.75 [ ] Rituximab for ABO-I LT (yes/no) 3 vs [ ] vs 1.25 [ ] vs 0 Living donor (yes/no) 3 vs [ ] vs 2.36 [ ] vs 66 Urgent indication (yes/no) 2 vs [ ] vs 2.08 [ ] vs 66 Pediatric (yes/no) 2 vs [ ] vs 1.95 [ ] vs 67 Bile leak 1.85 [ ] Rituximab for ABO-I LT (yes/no) 2 vs [ ] vs NA NA 0 vs NA Living donor (yes/no) 2 vs [ ] vs [ ] vs NA Urgent indication (yes/no) 0 vs 3 NA vs 1.85 [ ] NA NA vs 53 Pediatric (yes/no) 0 vs 3 NA vs 1.85 [ ] NA NA vs 53 Biliary stricture 1.37 [ ] Rituximab for ABO-I LT (yes/no) 4 vs [ ] vs 4.32 [ ] vs NA Living donor (yes/no) 4 vs [ ] vs 4.49 [ ] vs 0 Urgent indication (yes/no) 1 vs [ ] vs 1.44 [ ] 0.11 NA vs 42 Pediatric (yes/no) 0 vs 6 NA vs 1.52 [ ] NA NA vs 47 HV complication 1.60 [ ] 0.32 NA Rituximab for ABO-I LT (yes/no) 1 vs [ ] vs NA NA NA Living donor (yes/no) 1 vs [ ] vs NA NA NA Urgent indication (yes/no) 0 vs 1 NA vs 1.60 [ ] NA NA Pediatric (yes/no) 0 vs 1 NA vs 1.60 [ ] NA NA PV complication 1.83 [ ] Rituximab for ABO-I LT (yes/no) 3 vs [ ] vs 2.65 [ ] vs NA Living donor (yes/no) 3 vs [ ] vs 3.27 [ ] vs 0 Urgent indication (yes/no) 2 vs [ ] vs 1.19 [ ] vs 0 Pediatric (yes/no) 0 vs 5 NA vs 1.83 [ ] NA NA vs 0 HA complication 4.17 [ ] < Rituximab for ABO-I LT (yes/no) 3 vs [ ] vs 4.43 [ ] vs 53 Living donor (yes/no) 4 vs [ ] vs 4.44 [ ] vs 10 Urgent indication (yes/no) 3 vs [ ] vs 3.30 [ ] vs 0 Pediatric (yes/no) 1 vs [ ] vs 5.26 [ ] 0.11 NA vs 0 1 P value for overall effect or test for differences in subgroup analysis; 2 Stewart et al [35] reported graft survival rates of pediatric and adults, respectively. ABO-I: ABO-Incompatible; ACR: Acute cellular rejection; AMR: Antibody-mediated rejection; CMV: Cytomegalovirus; CR: Chronic rejection; HA: Hepatic artery; HV: Hepatic vein; LT: Liver transplantation; PV: Portal vein. adult ABO-I LT [52,53]. Egawa et al [52] reported that an advanced recipient age for ABO-I LDLT is associated with poor outcomes, including graft and patient survivals, intrahepatic biliary complications, and hepatic necrosis. Maternal anti-abo antibodies (Ab) begin to disappear from week two after birth, and neonates begin to produce their own reservoir of anti- ABO Ab from weeks 8-12 after birth, which reaches a level similar to that of adults by age 5-10 [54,55]. Thus, younger pediatric patients may be immunologically immature, showing lower anti-abo Ab levels and immature complement system [56,57], which could be a possible explanation for our result of pediatric graft survival September 21, 2017 Volume 23 Issue 35
12 A Song % [12.49, ] Shen % 9.93 [0.46,272.67] Toso % [0.81, ] Gugenhenim % [13.04, ] Total (95% CI) % [16.32, ] Total events 26 0 Heterogenity χ 2 = 3.39, df = 3 (P = 0.34); I 2 = 12% Test for overall effect: Z = 5.57 (P < ) B 0 Song % 0.85 [0.51, 1.41] Kim % 0.66 [0.24, 1.81] Kim % 0.97 [0.04, 24.67] lkegami % 1.52 [0.49, 4.75] Shen % 0.62 [0.06, 6.17] Heffron % 2.00 [0.47, 8.53] Toso % 1.72 [0.55, 5.36] Koukoutsis % 1.28 [0.18, 9.23] Heffron % 0.96 [0.33, 2.81] Cacciarelli % 2.86 [0.76, 10.75] Lo % 1.97 [0.85, 4.53] Sanchez % 4.09 [1.01, 16.58] Gugenheim % 1.15 [0.42, 3.15] Total (95%CI) % 1.23 [0.93, 1.62] Heterogenity χ 2 = 10.61, df = 12 (P = 0.68); I 2 = 0% Total events Test for overall effect: Z = 1.44 (P = 0.15) C Song % 1.11 [0.24, 5.09] lkegami % [2.49, ] Lo % 1.71 [0.18, 15.89] Gugenheim % 3.11 [0.80, 12.10] Total (95% CI) % 2.28 [1.00, 5.22] Total events 7 28 Heterogenity χ 2 = 5.17, df = 3 (P = 0.16); I 2 = 42% Test for overall effect: Z = 1.96 (P = 0.05) D Song % 0.81 [0.40, 1.65] Kim % 0.64 [0.30, 1.38] lkegami % 0.40 [0.50, 3.10] Shen % 0.84 [0.29, 2.45] Total (95% CI) % 0.72 [0.46, 1.14] Total events Heterogenity χ 2 = 0.58, df = 3 (P = 0.90); I 2 = 0% Test for overall effect: Z = 1.42 (P = 0.16) E Song % 0.73 [0.26, 2.10] Kim % 0.58 [0.21, 1.56] Shen % 1.40 [0.41, 4.80] Toso % 0.20 [0.03, 1.62] Total (95%CI) % 0.66 [0.37, 1.18] Total events Heterogenity χ 2 = 2.81, df = 3 (P = 0.42); I 2 = 0% Test for overall effect: Z = 1.40 (P = 0.16) 6527 September 21, 2017 Volume 23 Issue 35
13 F Song % 1.28 [0.36, 4.53] Kim % 1.85 [0.73, 4.69] lkegami % 3.75 [1.48, 9.50] Toso % 1.45 [0.45, 4.74] Saito % [2.48, ] Total (95% CI) % 2.64 [1.63, 4.29] Total events Heterogenity χ 2 = 7.02, df = 4 (P = 0.13); I 2 = 43% Test for overall effect: Z = 3.95 (P < ) Figure 4 Comparison of rejection and infection between ABO-incompatible and ABO-compatible liver transplantation. A: AMR; B: ACR; C: CR; D: Bacterial infection; E: Fungal infection; F: CMV infection. ABO-C: ABO-Compatible; ABO-I: ABO-incompatible; ACR: Acute cellular rejection; AMR: Antibody-mediated rejection; CMV: Cytomegalovirus; CR: Chronic rejection; LT: Liver transplantation. In this meta-analysis, cases that used rituximab in ABO-I LT patients [28-33] showed better 1-year graft survival after ABO-I LT than those that did not use rituximab [5,15,16,18,34,38-40]. Furthermore, in such cases, 1-, 3-, and 5-year graft survivals of ABO-I LT were comparable to those of ABO-C LT. On the other hand, biliary stricture and ACR tended to be more prevalent after ABO-I LT when rituximab was not used. There were no differences in AMR and patient survival in accordance with the use of rituximab. Rituximab is a chimeric human anti-cd20 monoclonal antibody, which destroys B cells via antibodydependent cell-mediated cytotoxicity, direct antigenantibody reaction, and complement-dependent cytotoxicity [58,59]. Since its first introduction as a prophylactic in Japan in 2002, multiple centers have used rituximab during ABO-I LT, which is considered to have contributed to the dramatic improvements in the outcomes of ABO-I LT [9,11,60,61]. In this meta-analysis, it was noted that using rituximab improved graft survival while reducing incidences of biliary stricture and ACR after ABO-I LT. However, its effects on AMR and patient survival were rather unclear, and we speculate this to be a result of excluding some studies from the subgroup analyses for lack of clear descriptions of desensitization methods in ABO-I LT [17,19,20, 35-37,41]. Meanwhile, studies that involved urgent indications, such as FHF, ALF, re-transplantation, and critically ill patients in the intensive care unit [5,15,17,19,20,33,34,39,40], showed worse 1-year graft survival but better 5-year patient survival in ABO-I LT than in ABO-C LT when compared to studies that did not involve urgent indications. Further, there were no significant differences in 3- and 5-year graft survivals between the two types of LT. This may be due to the fact that studies that only examined recipients with urgent indications mostly involved relatively lower prevalences of chronic liver disease and liver cancer but more advanced disease severity and inadequate desensitizations before ABO-I LT. Shaked et al [62] showed that there were no differences in biopsy-proven ACR and graft loss by rejection between LDLT and deceased donor liver transplantation (DDLT). However, our subgroup analysis showed that ACR was less prevalent after ABO-I LT in cases that only used living donor liver grafts [18,28-32,36] than in cases that did not. In other words, there were no differences in ACR in accordance with ABO compatibility in cases of LDLT, but incidences of ACR increased in cases of ABO-I LT using deceased donor liver grafts. It could be assumed that compared to DDLT, LDLT has immunological advantages resulting from high genetic similarities between organ donor and recipient and short cold ischemic times [63,64]. Further, biliary complications, such as bile leak and biliary stricture, are known to be more prevalent in LDLT with inherent weakness arising from a small duct size, possible multiplicity of bile duct, and cutting liver parenchyma, compared to those in DDLT [65-68]. However, our analysis revealed that using only living donor liver grafts [18,28-32,36] resulted in fewer cases of biliary stricture in ABO-I LT. One of the possible reasons is that studies only involving deceased donor grafts in our meta-analysis of biliary stricture [40,41] were published at least 20 years earlier than the studies involving living donor allografts [28-31]. Further, some of them involved urgent indications [40], which would have resulted in the use of markedly different desensitization and immunosuppression methods and surgical techniques from those employed today. Meanwhile, in this meta-analysis, a potential publication bias was detected in the 1-year patient survival. Possible sources of asymmetry in the funnel plot would most definitely include small study effects, but poor methodological quality, true heterogeneity, artifactual, and chance could be other sources as well [21,25,69-72]. This review has some limitations. First, it was based on non-randomized controlled trials because it is practically impossible to randomly allocate patients into either ABO-C LT or ABO-I LT group. Second, some articles lacked clear descriptions about patient demographics and study design, such as age, enrollment criteria, graft type, and desensitization and immunosuppression methods. Third, some results showed heterogeneity and potential publication bias September 21, 2017 Volume 23 Issue 35
14 A Study or subgroup Events Total Events Total Weight M-H. Random. 95%CI M-H. Random. 95%CI Kim % 0.82 [0.34, 1.97] Lee % 2.37 [1.27, 4.41] Shen % 0.94 [0.16, 5.40] Iwamoto % 1.56 [0.38, 6.38] Toso % 1.39 [0.44, 4.34] Heffron % 1.20 [0.24, 5.87] Cacciarelli % 1.35 [0.15, 11.86] Sanchez % [7.97, ] Total (95% CI) % 1.75 [0.89, 3.43] Total events Heterogenity Tau 2 = 0.45 χ 2 = 15.22, df = 7 (P = 0.03); I 2 = 54% Test for overall effect: Z = 1.63 (P = 0.10) B Study or subgroup Events Total Events Total Weight M-H. Random. 95%CI M-H. Random. 95%CI Kim % 0.81 [0.27, 2.46] Kim % 1.54 [0.27, 8.98] Sanchez % [1.17, ] Total (95% CI) % 1.85 [0.46, 7.39] Total events Heterogenity Tau 2 = 0.80 χ 2 = 4.25, df = 2 (P = 0.12); I 2 = 53% 0 Test for overall effect: Z = 0.87 (P = 0.39) C Odds Ratio Study or subgroup Events Total Events Total Weight M-H. Random. 95%CI M-H. Fixed. 95%CI Song % 1.79 [1.24, 2.57] Kim % 0.58 [0.20, 1.70] Kim % 0.31 [0.02, 5.99] lkegami % 0.75 [0.21, 2.63] Lo % 4.32 [1.18, 15.81] Sanchez % 5.61 [0.25, ] Total (95% CI) % 1.37 [0.70, 2.70] Total events Heterogenity Tau 2 = 0.29 χ 2 = 9.36, df = 5 (P = 0.10); I 2 = 47% Test for overall effect: Z = 0.91 (P = 0.36) D Favours ABO-I Favours ABO-C ABO-I ABO-C Odds rati0 Odds ratio Song % 2.78 [0.51, 15.28] Kim % 3.08 [0.19, 51.20] lkegami % 1.51 [0.08, 27.83] Iwamoto % [0.63, ] Toso % 3.78 [0.98, 14.54] Heffron % 0.47 [0.03, 8.56] Lo % 5.54[ 1.17, 26.15] Sanchez % [0.77, ] Gugenheim % [2.32, 56.05] Total (95% CI) % 4.17 [2.26, 7.67] Total events Heterogenity: χ 2 = 5.88, df = 8 (P = 0.66); I 2 = 0% Test for overall effect: Z = 4.58 (P < ) E Song % 1.60 [0.64, 4.00] Total (95%CI) % 1.60 [0.64, 4.00] Total events 6 21 Heterogenity: Not applicable Test for overall effect: Z = 1.00 (P < 0.32) Favours ABO-I Favours ABO-C 6529 September 21, 2017 Volume 23 Issue 35
15 F Song % 1.39 [0.15, 12.45] Kim % 0.41 [0.02, 8.14] lkegami % 3.03 [0.35, 25.97] Toso % 3.75 [0.62, 22.71] Gugenheim % 2.65 [0.29, 24.07] Total (95% CI) % 1.83 [0.70, 4.76] Total events 5 23 Heterogenity: χ 2 = 1.96, df = 4 (P = 0.74); I 2 = 0% Test for overall effect: Z = 1.23 (P = 0.22) Figure 5 Comparison of biliary and vascular complications between ABO-Incompatible and ABO-Compatible liver transplantation. A: Overall biliary complication; B: Bile leak; C: Biliary stricture; D: HA complication; E: HV complication; F: PV complication. ABO-C: ABO-compatible; ABO-I: ABO-incompatible; HA: Hepatic artery; HV: Hepatic vein; LT: Liver transplantation; PV: Portal vein. A Standard error yr patient survival B Standard error yr patient survival Figure 6 (A) Funnel plot and (B) Adjusted funnel plot using the Trim-and-Fill method of studies reporting on 1-yr patient survival after ABO-incompatible liver transplantation vs ABO-Compatible liver transplantation. Closed circles represent observed published studies; open circles represent imputed unpublished studies. ABO-C: ABO-compatible; ABO-I: ABO-incompatible; LT: Liver transplantation. This meta-analysis is the largest review that integrating more than 8000 cases of ABO-I LT and ABO-C LT. It revealed that ABO-I LT is associated with poorer graft survival and higher prevalence of AMR, CR, CMV infection, overall biliary complication, and HA complication than those of ABO-C LT. There were no significant differences in patient survival, ACR, bacterial infection, fungal infection, bile leak, biliary stricture, and HV and PV complications in accordance with ABO compatibility. In our subgroup analysis, graft survival in ABO-I LT was found to be comparable to that in ABO-C LT in pediatric patients. Use of rituximab was associated with better graft survival in ABO-I LT. In cases of DDLT, there was a higher incidence of ACR after ABO-I LT. Although substantial improvements and advances have been made in liver transplantations across the ABO blood group barrier, persistent limitations call for further endeavors to achieve better outcomes. ACKNOWLEDGMENTS The authors wish to thank Jae Ryong Shim, MD for his contribution to this article. COMMENTS Background Increased ABO-incompatible (ABO-I) liver transplantation (LT) is inevitable due to reduced organ donation and difficulty in finding suitable ABO-compatible (ABO-C) allografts. In particular, the importance of ABO-I LT is increasing in Asian countries where the use rate of ABO-I liver allograft is higher than that of Western countries due to the large number of organ donations in the family in living donor liver transplantation. Research frontiers Outcomes after LT in accordance with ABO compatibility is still controversial. Therefore, it is necessary to evaluate the possibilities and the limitations of ABO-I LT by meta-analysis integrating outcomes of previous reports comparing ABO-I and ABO-C LT. Innovations and breakthroughs ABO-I LT is comparable to ABO-C LT in terms of patient survival, but is inferior in graft survival, antibody-mediated rejection, chronic rejection, cytomegalovirus infection, overall biliary complication, and hepatic artery complication. However, in pediatric patients and those using rituximab, the graft survival of ABO-I LT was comparable to that of ABO-C LT. Applications The authors performed a meta-analysis of outcomes after liver transplantation in accordance with ABO compatibility. In this way, the possibilities and the limitations of ABO-I LT can be clarified September 21, 2017 Volume 23 Issue 35
BK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationTransplantation in Australia and New Zealand
Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia
More informationSystematic Reviews and Meta- Analysis in Kidney Transplantation
Systematic Reviews and Meta- Analysis in Kidney Transplantation Greg Knoll MD MSc Associate Professor of Medicine Medical Director, Kidney Transplantation University of Ottawa and The Ottawa Hospital KRESCENT
More informationABO. ABO ABO ABO ABO ABO ABO ABO ABO. Key words ABO. Alexandre ABO ABO. double filtration plasmapheresis, DFPP. antibody-mediated rejection, AMR
ABO ABO ABO ABO ABO ABO ABO ABO ABO ABO.. ABO ABO. ABO. ABO ABO Key words ABO ABO A B antibody-mediated rejection, AMR Alexandre ABO double filtration plasmapheresis, DFPP ABO ABO n ABO n p-value R.....
More informationFeasible usage of ABO incompatible grafts in living donor liver transplantation
Original Article Feasible usage of ABO incompatible grafts in living donor liver transplantation Toru Ikegami, Tomoharu Yoshizumi, Yuji Soejima, Hideaki Uchiyama, Ken Shirabe, Yoshihiko Maehara Department
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2010 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE I INTRODUCTION 1 II
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2014 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE II TRANSPLANTATION Section
More informationLive Donor Liver Transplantation: A Life Saving Option for End Stage Liver Disease
Live Donor Liver Transplantation: A Life Saving Option for End Stage Liver Disease Abhi Humar, MD Clinical Director, Thomas E. Starzl Transplantation Institute 1 PITTSBURGH THE BIRTHPLACE OF LIVER TRANSPLANTATION
More informationABO INCOMPATILIBITY AND TRANSPLANTATION
ABO INCOMPATILIBITY AND TRANSPLANTATION Aleksandar Mijovic Consultant Haematologist/Senior Lecturer King s College Hospital/NHS Blood and Transplant London, UK RTC Edu Meeting May 2017 ABO antigens Expressed
More informationTime of onset and predictors of biphasic anaphylactic reactions: A systematic. A. To describe the time frame where biphasic reactions can occur.
KER UNIT - PROTOCOL OF REVIEW TITLE Time of onset and predictors of biphasic anaphylactic reactions: A systematic review and meta-analysis of the literature REVIEW QUESTION A. To describe the time frame
More informationPOST TRANSPLANT OUTCOMES IN PSC
POST TRANSPLANT OUTCOMES IN PSC Kidist K. Yimam, MD Medical Director, Autoimmune Liver Disease Program Division of Hepatology and Liver Transplantation California Pacific Medical Center (CPMC) PSC Partners
More informationSignificance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis
Significance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis Hatem Ali 1,2, Atif Mohiuddin 2,3, Ajay Sharma 2,3, Mohsen El Kosi 2,4 and Ahmed Halawa
More informationHLA and Non-HLA Antibodies in Transplantation and their Management
HLA and Non-HLA Antibodies in Transplantation and their Management Luca Dello Strologo October 29 th, 2016 Hystory I 1960 donor specific antibodies (DSA): first suggestion for a possible role in deteriorating
More informationRecipient Outcomes after ABO-Incompatible Liver Transplantation: A Systematic Review and Meta-Analysis
Recipient Outcomes after ABO-Incompatible Liver Transplantation: A Systematic Review and Meta-Analysis Jian Wu 1,2,3, SunYi Ye 1,2,3, XiaoFeng Xu 1,2,3, Haiyang Xie 1,2,3, Lin Zhou 1,2,3, ShuSen Zheng
More informationEuropean Risk Management Plan. Measures impairment. Retreatment after Discontinuation
European Risk Management Plan Table 6.1.4-1: Safety Concern 55024.1 Summary of Risk Minimization Measures Routine Risk Minimization Measures Additional Risk Minimization Measures impairment. Retreatment
More informationPediatric Liver Transplantation Outcomes in Korea
ORIGINAL ARTICLE Cell Therapy & Organ Transplantation http://dx.doi.org/6/jkms.8..4 J Korean Med Sci 0; 8: 4-47 Pediatric Liver Transplantation Outcomes in Korea Jong Man Kim,, * Kyung Mo Kim,, * Nam-Joon
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationLiver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995
Liver Transplantation for Alcoholic Liver Disease in the United States: 1988 to 1995 Steven H. Belle, Kimberly C. Beringer, and Katherine M. Detre T he Scientific Liver Transplant Registry (LTR) was established
More informationHealth technology Two prophylaxis schemes against organ rejection in renal transplantation were compared in the study:
An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation Polsky D, Weinfurt K P, Kaplan B, Kim J, Fastenau J, Schulman K A Record Status
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews High-dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents and young adults with first
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationChapter 6: Transplantation
Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.
More informationThis study is currently recruiting participants.
A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation This study is currently recruiting
More informationABO-Incompatible Adult Living Donor Liver Transplantation Under the Desensitization Protocol With Rituximab
American Journal of Transplantation 2016; 16: 157 170 Wiley Periodicals Inc. C Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.13444
More informationWhat is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham
What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham SYMPHONY Study Ekberg et al. NEJM 2008 Excluded: DCD kidneys; CIT>30hours;
More informationTolerance Induction in Transplantation
Tolerance Induction in Transplantation Reza F. Saidi, MD, FACS, FICS Assistant Professor of Surgery Division of Organ Transplantation Department of Surgery University of Massachusetts Medical School Percent
More informationDesensitization in Kidney Transplant. James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver
Desensitization in Kidney Transplant James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Organ Shortage Currently there are >90,000 patients on the kidney
More informationImpact of Rituximab Desensitization on Blood-Type-Incompatible Adult Living Donor Liver Transplantation: A Japanese Multicenter Study
Wiley Periodicals Inc. C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.12520 Impact of Rituximab Desensitization on Blood-Type-Incompatible
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More informationFigure 1. Actuarial survival of patients with ABO I, ABO compatible, and ABO identical grafts.
New Insights into Antibody Mediated Graft Injury after Pediatric Liver Transplantation S.V. McDiarmid MD Professor of Pediatrics and Surgery David Geffen School of Medicine University of California, Los
More informationDate: 23 June Context and policy issues:
Title: Basiliximab for Immunosuppression During a Calcineurin Inhibitor Holiday in Renal Transplant Patients with Acute Renal Dysfunction: Guidelines for Use and a Clinical and Cost-Effectiveness Review
More informationLong-term prognosis of BK virus-associated nephropathy in kidney transplant recipients
Original Article Kidney Res Clin Pract 37:167-173, 2018(2) pissn: 2211-9132 eissn: 2211-9140 https://doi.org/10.23876/j.krcp.2018.37.2.167 KIDNEY RESEARCH AND CLINICAL PRACTICE Long-term prognosis of BK
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationABO-incompatible kidney transplantation in elderly patients over 60 years of age
Int Urol Nephrol (2012) 44:1563 1570 DOI 10.1007/s11255-012-0231-z NEPHROLOGY - ORIGINAL PAPER ABO-incompatible kidney transplantation in elderly patients over 60 years of age Junji Uchida Tomoaki Iwai
More informationReliability of Echocardiography Measurement of Patent Ductus Arteriosus Minimum Diameter: A Meta-analysis
International Journal of Cardiovascular and Cerebrovascular Disease 4(): 15-19, 016 DOI: 10.13189/ijccd.016.04001 http://www.hrpub.org Reliability of Echocardiography Measurement of Patent Ductus Arteriosus
More informationTreatment of Chronic Graft versus Host Disease. Daniel Weisdorf MD University of Minnesota
Treatment of Chronic Graft versus Host Disease Daniel Weisdorf MD University of Minnesota October 2013 Infections Transplant Events d-8 0 1mo 3mo 6mo Conditioning Transplant Engraftment Mucositis Organ
More informationCURRICULUM VITAE July 5, Name Chang-Kwon Oh. Date of Birth August 15, 1961
CURRICULUM VITAE July 5, 2014 Name Chang-Kwon Oh Date of Birth August 15, 1961 Present Academic & Hospital Appointment Professor, Department of Surgery Ajou University, School of Medicine Chief, Department
More informationPharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents
BUMC Proceedings 1999;12:110-112 Pharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents CHERYLE GURK-TURNER, RPH Department of Pharmacy Services, BUMC wo mouse/human
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated
More informationCochrane Pregnancy and Childbirth Group Methodological Guidelines
Cochrane Pregnancy and Childbirth Group Methodological Guidelines [Prepared by Simon Gates: July 2009, updated July 2012] These guidelines are intended to aid quality and consistency across the reviews
More informationTitle: What is the role of pre-operative PET/PET-CT in the management of patients with
Title: What is the role of pre-operative PET/PET-CT in the management of patients with potentially resectable colorectal cancer liver metastasis? Pablo E. Serrano, Julian F. Daza, Natalie M. Solis June
More informationAmerican Journal of Internal Medicine
American Journal of Internal Medicine 2016; 4(3): 49-59 http://www.sciencepublishinggroup.com/j/ajim doi: 10.11648/j.ajim.20160403.12 ISSN: 2330-4316 (Print); ISSN: 2330-4324 (Online) The Effect of Dose-Reduced
More informationLiver Transplantation
1 Liver Transplantation Department of Surgery Yonsei University Wonju College of Medicine Kim Myoung Soo M.D. ysms91@wonju.yonsei.ac.kr http://gs.yonsei.ac.kr History Development of Liver transplantation
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationMINDFULNESS-BASED INTERVENTIONS IN EPILEPSY
03 March 2016; v.1 MINDFULNESS-BASED INTERVENTIONS IN EPILEPSY AIM This review aimed to evaluate the effectiveness of mindfulness as a therapeutic intervention for people with epilepsy. METHODS Criteria
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Closed reduction methods for acute anterior shoulder dislocation [Cochrane Protocol] Kanthan Theivendran, Raj Thakrar, Subodh Deshmukh,
More informationChapter 22: Hematological Complications
Chapter 22: Hematological Complications 22.1: Perform a complete blood count at least (Not Graded): daily for 7 days, or until hospital discharge, whichever is earlier; two to three times per week for
More informationSUPPLEMENTARY DATA. Supplementary Figure S1. Search terms*
Supplementary Figure S1. Search terms* *mh = exploded MeSH: Medical subject heading (Medline medical index term); tw = text word; pt = publication type; the asterisk (*) stands for any character(s) #1:
More informationCochrane Breast Cancer Group
Cochrane Breast Cancer Group Version and date: V3.2, September 2013 Intervention Cochrane Protocol checklist for authors This checklist is designed to help you (the authors) complete your Cochrane Protocol.
More informationResults. NeuRA Motor dysfunction April 2016
Introduction Subtle deviations in various developmental trajectories during childhood and adolescence may foreshadow the later development of schizophrenia. Studies exploring these deviations (antecedents)
More informationLiver Transplant Immunosuppression
Liver Transplant Immunosuppression Michael Daily, MD, MS, FACS Surgical Director, Kidney and Pancreas Transplantation University of Kentucky Medical Center Disclosures No financial disclosures I will be
More informationStrategies for Desensitization
Strategies for Desensitization Olwyn Johnston MB, MRCPI, MD, MHSc BC Nephrology Day October 8 th 2010 Pre-transplant crossmatch (CMX) with donor lymphocytes has been standard of practice Positive CDC CXM
More informationLiterature Review: Transplantation July 2010-June 2011
Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney
More informationMarta Farrero Torres₁, Marcelo Pando₂, Dolly Tyan₂, Hannah Valantine₃, Spenser Smith₃, Kiran Khush₃
Development of HLA donor specific antibodies after heart transplantation: importance of a new method to detect the first component of the complement cascade Marta Farrero Torres₁, Marcelo Pando₂, Dolly
More informationEvaluating the results of a Systematic Review/Meta- Analysis
Open Access Publication Evaluating the results of a Systematic Review/Meta- Analysis by Michael Turlik, DPM 1 The Foot and Ankle Online Journal 2 (7): 5 This is the second of two articles discussing the
More informationImmunopathology of T cell mediated rejection
Immunopathology of T cell mediated rejection Ibrahim Batal MD Columbia University College of Physicians & Surgeons New York, NY, USA Overview Pathophysiology and grading of TCMR TCMR is still a significant
More informationThe Expression of Beclin-1 in Hepatocellular Carcinoma and Non-Tumor Liver Tissue: A Meta-Analysis
The Expression of Beclin-1 in Hepatocellular Carcinoma and Non-Tumor Liver Tissue: A Meta-Analysis Zhiqiang Qin¹, Xinjuan Yu², Jinkun Wu¹, Mei Lin¹ 1 Department of Pathology, School of Basic Medicine,
More informationPaediatric Liver Transplant Programme Wits Donald Gordon Medical Centre
Paediatric Liver Transplant Programme Wits Donald Gordon Medical Centre J Loveland, J Botha, R Britz, B Strobele, S Rambarran, A Terblanche, C Kock, P Walabh, M Beretta, M Duncan et al 1817 reveal the
More informationCitation Characteristics of Research Published in Emergency Medicine Versus Other Scientific Journals
ORIGINAL CONTRIBUTION Citation Characteristics of Research Published in Emergency Medicine Versus Other Scientific From the Division of Emergency Medicine, University of California, San Francisco, CA *
More informationProblem solving therapy
Introduction People with severe mental illnesses such as schizophrenia may show impairments in problem-solving ability. Remediation interventions such as problem solving skills training can help people
More information3/6/2017. Prevention of Complement Activation and Antibody Development: Results from the Duet Trial
Prevention of Complement Activation and Antibody Development: Results from the Duet Trial Jignesh Patel MD PhD FACC FRCP Medical Director, Heart Transplant Cedars-Sinai Heart Institute Disclosures Name:
More informationProgress in Pediatric Kidney Transplantation
Send Orders for Reprints to reprints@benthamscience.net The Open Urology & Nephrology Journal, 214, 7, (Suppl 2: M2) 115-122 115 Progress in Pediatric Kidney Transplantation Jodi M. Smith *,1 and Vikas
More informationAppendix 1: Systematic Review Protocol [posted as supplied by author]
Appendix 1: Systematic Review Protocol [posted as supplied by author] Title Physical Activity and Risks of Breast Cancer, Colon Cancer,, Ischemic Heart Disease and Ischemic Stroke Events: A Systematic
More informationSurveillance report Published: 9 January 2017 nice.org.uk
Surveillance report 2017 Caesarean section (2011) NICE guideline CG132 Surveillance report Published: 9 January 2017 nice.org.uk NICE 2017. All rights reserved. Contents Surveillance decision... 3 Reason
More informationTransfusion support in Transplantation
Transfusion support in Transplantation Patricia Campbell University of Alberta Hospitals University of Alberta Objectives UofA transplant programs What we do and why? HLA and ABO incompatible transplants
More informationLiver transplantation in mainland China: the overview of CLTR 2011 annual scientific report. Wang, H; Jiang, W; Zhou, Z; Long, J; Li, W; Fan, ST
Title Liver transplantation in mainland China: the overview of CLTR 211 annual scientific report Author(s) Wang, H; Jiang, W; Zhou, Z; Long, J; Li, W; Fan, ST Citation Hepatobiliary Surgery and Nutrition,
More informationEmerging Drug List EVEROLIMUS
Generic (Trade Name): Manufacturer: Everolimus (Certican ) Novartis Pharmaceuticals NO. 57 MAY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence: For use with cyclosporine
More informationA systemic review and meta-analysis for prognostic values of pretreatment lymphocyte-to-monocyte ratio on gastric cancer
831094EJI0010.1177/2058739219831094European Journal of InflammationLi et al. letter2019 Letter to the Editor A systemic review and meta-analysis for prognostic values of pretreatment lymphocyte-to-monocyte
More informationAmerican Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc.
American Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc. 2009 The Authors Journal compilation 2009 The American Society of Transplantation and the American Society of Transplant
More informationSystematic review of the non- specific effects of BCG, DTP and measles containing vaccines
Systematic review of the non- specific effects of BCG, DTP and measles containing vaccines Higgins JPT, Soares- Weiser K, Reingold A 13 March 2014 Contents 1 Executive Summary... 3 2 Background... 4 3
More informationOUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes
nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin
More informationZhengtao Liu 1,2,3*, Shuping Que 4*, Lin Zhou 1,2,3 Author affiliation:
Dose-response Relationship of Serum Uric Acid with Metabolic Syndrome and Non-alcoholic Fatty Liver Disease Incidence: AMeta-analysis of Prospective Studies Zhengtao Liu 1,2,3*, Shuping Que 4*, Lin Zhou
More informationManagement of Rejection
Management of Rejection I have no disclosures Disclosures (relevant or otherwise) Deborah B Adey, MD Professor of Medicine University of California, San Francisco Kidney and Pancreas Transplant Center
More informationBlood Group Incompatible Renal Transplantation and Apheresis. Liz Wright Clinical Nurse Specialist Great Ormond Street Hospital NHS FT
Blood Group Incompatible Renal Transplantation and Apheresis Liz Wright Clinical Nurse Specialist Great Ormond Street Hospital NHS FT Background There is growing interest in transplantation across the
More informationCochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library)
A systematic review of smoking cessation and relapse prevention interventions in parents of babies admitted to a neonatal unit (after delivery) Divya Nelson, Sarah Gentry, Caitlin Notley, Henry White,
More informationA protocol for a systematic review on the impact of unpublished studies and studies published in the gray literature in meta-analyses
Systematic Reviews This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon. A protocol for a systematic
More informationAppendix 1: Medline Search Strategy
Appendix 1: Medline Search Strategy 1. exp Parkinson Disease/ 2. exp Incidence/ 3. exp Prevalence/ 4. exp Epidemiology/ 5. 2 or 3 or 4 6. 1 and 5 7. *Parkinson Disease/ep [Epidemiology] 8. 6 or 7 9. 8
More informationThe effect of resection of the primary tumour for stage IV colorectal cancer on patient survival: a systematic review and meta-analysis
The effect of resection of the primary tumour for stage IV colorectal cancer on patient survival: a systematic review and meta-analysis C.Clancy, J.P. Burke, M. Barry, M.F Kalady, J.C. Coffey Dept. of
More informationThe addition of anti-cd25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients GUIDELINES SEARCH STRATEGY
nep_2.fm Page 5 Friday, January 26, 200 6:46 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology120-558 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 20012S1584MiscellaneousCalcineurin
More informationAppendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014
Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014 The notification letter which contains details of the decision to widen the restriction criteria for rituximab and eltrombopag
More informationTakashi Yagisawa 1,2*, Makiko Mieno 1,3, Norio Yoshimura 1,4, Kenji Yuzawa 1,5 and Shiro Takahara 1,6
Yagisawa et al. Renal Replacement Therapy (2016) 2:68 DOI 10.1186/s41100-016-0080-9 POSITION STATEMENT Current status of kidney transplantation in Japan in 2015: the data of the Kidney Transplant Registry
More informationAlectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis
Showa Univ J Med Sci 30 2, 309 315, June 2018 Original Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis Ryo MANABE 1, Koichi ANDO
More informationOverall Goals and Objectives for Transplant Hepatology EPAs:
Overall Goals and Objectives for Transplant Hepatology EPAs: 1. DIAGNOSTIC LIST During the one-year Advanced Pediatric Transplant Hepatology Program, fellows are expected to develop comprehensive skills
More informationSummary of Results for Laypersons
What was the Study Called? Summary of Results for Laypersons A Multicenter, Three Arm, Randomized, Open Label Clinical Study to Compare Renal Function in Liver Transplant Recipients Receiving an Immunosuppressive
More informationC2 Training: August 2010
C2 Training: August 2010 Introduction to meta-analysis The Campbell Collaboration www.campbellcollaboration.org Pooled effect sizes Average across studies Calculated using inverse variance weights Studies
More informationTransplantation in highly sensitised patients treated with intravenous immunoglobulin and Rituximab
ORIGINAL ARTICLE Advance Access publication 1 February 2010 Transplantation in highly sensitised patients treated with intravenous immunoglobulin and Rituximab Ana Carina Ferreira 1, Sandra Brum 1, Vasco
More informationFixed Effect Combining
Meta-Analysis Workshop (part 2) Michael LaValley December 12 th 2014 Villanova University Fixed Effect Combining Each study i provides an effect size estimate d i of the population value For the inverse
More informationBackground: Traditional rehabilitation after total joint replacement aims to improve the muscle strength of lower limbs,
REVIEWING THE EFFECTIVENESS OF BALANCE TRAINING BEFORE AND AFTER TOTAL KNEE AND TOTAL HIP REPLACEMENT: PROTOCOL FOR A SYSTEMATIC RE- VIEW AND META-ANALYSIS Background: Traditional rehabilitation after
More informationVictims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham
Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham Disclosure Employee: CTI Clinical Trials and Consulting
More informationRobotic Bariatric Surgery. Richdeep S. Gill, MD Research Fellow Center for the Advancement of Minimally Invasive Surgery (CAMIS)
Robotic Bariatric Surgery Richdeep S. Gill, MD Research Fellow Center for the Advancement of Minimally Invasive Surgery (CAMIS) Background Over 500 million obese individuals worldwide Bariatric surgery
More informationSuccessful ABO-Incompatible Pediatric Liver Transplantation Utilizing Standard Immunosuppression With Selective Postoperative Plasmapheresis
LIVER TRANSPLANTATION 12:972-978, 2006 ORIGINAL ARTICLE Successful ABO-Incompatible Pediatric Liver Transplantation Utilizing Standard Immunosuppression With Selective Postoperative Plasmapheresis Thomas
More informationWhy so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation
Why so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation Stephen J Tomlanovich MD Objectives of this Talk Define the sensitized patient Describe the scope of the problem for a
More informationABO mismatched Renal Transplants
ABO mismatched Renal Transplants Nicos Kessaris Renal Transplant Surgeon St George s Hospital, London 7 th March 2012 Why? Protocol Risks Experience abroad Experience in UK Experience at St George s Conclusions
More informationAPHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS
APHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS GOW AREPALLY, MD MEDICAL DIRECTOR DUKE THERAPEUTIC APHERESIS SERVICE ASSOCIATE PROFESSOR, MEDICINE AMERICAN SOCIETY FOR APHERESIS MAY 25 TH 2013 OVERVIEW
More informationShould red cells be matched for transfusions to patients listed for renal transplantation?
Should red cells be matched for transfusions to patients listed for renal transplantation? Dr M.Willicombe Imperial College Renal and Transplant Centre, Hammersmith Hospital Should red cells be matched
More informationLong term liver transplant management
Long term liver transplant management Dr Bill Griffiths Cambridge Liver Unit Royal College of Physicians 5.7.17 Success of Liver Transplantation Current survival, 1 st elective transplant: 1 yr survival
More informationSolid Organ Transplant
Solid Organ Transplant Lee R. Goldberg, MD, MPH, FACC Associate Professor of Medicine Medical Director, Heart Failure and CardiacTransplant Program University of Pennsylvania Disclosures Thoratec Consulting
More informationTraumatic brain injury
Introduction It is well established that traumatic brain injury increases the risk for a wide range of neuropsychiatric disturbances, however there is little consensus on whether it is a risk factor for
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More information